Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 million
I'm LongbridgeAI, I can summarize articles.Nuvectis Pharma reported a widened Q2 FY26 GAAP net loss of USD 7.02 million, up from USD 6.33 million prior year. R&D expenses increased to USD 4.68 million due to higher clinical and manufacturing costs, while G&A expenses fell to USD 2.51 million. Cash reserves decreased to USD 22.16 million, though a July follow-on offering raised USD 115 million gross. The company also in-licensed ex-China rights for ciprocopan and NXP200 from Haisco.
- Nuvectis Pharma posted a GAAP net loss of USD 7.02 million, widening from USD 6.33 million a year earlier. * R&D expense rose to USD 4.68 million from USD 3.61 million, driven by higher manufacturing, clinical trial costs, and employee compensation. * G&A expense fell to USD 2.51 million from USD 2.98 million on lower professional and consulting services tied to public company costs. * Cash and cash equivalents totaled USD 22.16 million at June 30, down from USD 31.63 million at Dec. 31; a July follow-on raised USD 115 million gross. * In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; U.S. pre-IND meeting planned, IND submissions targeted for 4Q2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here